BR112012026509B1 - composto derivado de benzamida, métodos para preparar o dito composto ou um sal farmaceuticamente aceitável deste e uso do mesmo para prevenção, tratamento ou alívio de uma doença devida à eficácia atenuada de um receptor 5-ht4 em um mamífero - Google Patents

composto derivado de benzamida, métodos para preparar o dito composto ou um sal farmaceuticamente aceitável deste e uso do mesmo para prevenção, tratamento ou alívio de uma doença devida à eficácia atenuada de um receptor 5-ht4 em um mamífero Download PDF

Info

Publication number
BR112012026509B1
BR112012026509B1 BR112012026509-1A BR112012026509A BR112012026509B1 BR 112012026509 B1 BR112012026509 B1 BR 112012026509B1 BR 112012026509 A BR112012026509 A BR 112012026509A BR 112012026509 B1 BR112012026509 B1 BR 112012026509B1
Authority
BR
Brazil
Prior art keywords
compound
formula
methyl
chloro
amino
Prior art date
Application number
BR112012026509-1A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112012026509A2 (pt
Inventor
Soon-Hoe Kim
Weon-Bin Im
Sung-Hak Choi
Sun-Ho Choi
Ju-Hee Sohn
Hyun-Jung Sung
Miyeon KIM
Kang-Hun Cho
Tae-Kyoung Sohn
Original Assignee
Dong-A Pharm.Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong-A Pharm.Co., Ltd. filed Critical Dong-A Pharm.Co., Ltd.
Publication of BR112012026509A2 publication Critical patent/BR112012026509A2/pt
Publication of BR112012026509B1 publication Critical patent/BR112012026509B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
BR112012026509-1A 2010-04-23 2011-04-18 composto derivado de benzamida, métodos para preparar o dito composto ou um sal farmaceuticamente aceitável deste e uso do mesmo para prevenção, tratamento ou alívio de uma doença devida à eficácia atenuada de um receptor 5-ht4 em um mamífero BR112012026509B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2010-0038039 2010-04-23
KR1020100038039A KR101180174B1 (ko) 2010-04-23 2010-04-23 신규한 벤즈아미드 유도체
PCT/KR2011/002759 WO2011132901A2 (en) 2010-04-23 2011-04-18 Novel benzamide derivatives

Publications (2)

Publication Number Publication Date
BR112012026509A2 BR112012026509A2 (pt) 2017-10-31
BR112012026509B1 true BR112012026509B1 (pt) 2021-01-19

Family

ID=44834616

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012026509-1A BR112012026509B1 (pt) 2010-04-23 2011-04-18 composto derivado de benzamida, métodos para preparar o dito composto ou um sal farmaceuticamente aceitável deste e uso do mesmo para prevenção, tratamento ou alívio de uma doença devida à eficácia atenuada de um receptor 5-ht4 em um mamífero

Country Status (19)

Country Link
US (1) US9221790B2 (cg-RX-API-DMAC7.html)
EP (1) EP2560955B1 (cg-RX-API-DMAC7.html)
JP (1) JP5564147B2 (cg-RX-API-DMAC7.html)
KR (1) KR101180174B1 (cg-RX-API-DMAC7.html)
CN (1) CN102844301B (cg-RX-API-DMAC7.html)
AU (1) AU2011243393B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012026509B1 (cg-RX-API-DMAC7.html)
CA (1) CA2794176C (cg-RX-API-DMAC7.html)
ES (1) ES2594708T3 (cg-RX-API-DMAC7.html)
IL (1) IL222491A (cg-RX-API-DMAC7.html)
MX (1) MX2012011721A (cg-RX-API-DMAC7.html)
MY (1) MY162554A (cg-RX-API-DMAC7.html)
NZ (1) NZ602612A (cg-RX-API-DMAC7.html)
PH (1) PH12012501843A1 (cg-RX-API-DMAC7.html)
RU (1) RU2536688C2 (cg-RX-API-DMAC7.html)
SG (1) SG184350A1 (cg-RX-API-DMAC7.html)
UA (1) UA107702C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011132901A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201207903B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101341693B1 (ko) 2011-03-16 2013-12-16 동아에스티 주식회사 생약추출물을 함유하는 퇴행성 신경질환의 치료 및 예방을 위한 조성물
KR101341692B1 (ko) 2011-03-16 2013-12-20 동아에스티 주식회사 복합생약추출물을 함유하는 당뇨병성 말초 신경병증의 치료 및 예방을 위한 조성물
KR101457789B1 (ko) 2013-02-13 2014-11-03 동아제약 주식회사 상처 치료용 필름형성 약제학적 조성물 및 그의 제조방법
WO2015012515A1 (ko) 2013-07-25 2015-01-29 동아에스티 주식회사 벤즈아미드 유도체의 제조방법, 그의 제조에 사용되는 새로운 중간체 및 상기 중간체의 제조방법
CN104230889A (zh) * 2014-08-29 2014-12-24 南京大学 环丙沙星衍生物及其制备方法与用途
KR102394635B1 (ko) * 2015-03-31 2022-05-09 (주)아모레퍼시픽 5-아다만탄-1-일-n-(2,4-다이하이드록시벤질)-2,4-다이메톡시벤즈아마이드를 함유하는 항산화 또는 항노화 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1507462A (en) 1974-03-21 1978-04-12 Gallardo Antonio Sa N-heterocyclic substituted benzamides methods for their preparation and compositions containing them
US5137896A (en) 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4962115A (en) 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
KR970702247A (ko) 1994-03-30 1997-05-13 고야 마사시 벤조산 화합물 및 이들의 약제로서의 용도(benzoic acid compound and use thereof as medicine)
US5864039A (en) 1994-03-30 1999-01-26 Yoshitomi Pharmaceutical Industries, Ltd. Benzoic acid compounds and use thereof as medicaments
TW402591B (en) * 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
ATE386720T1 (de) 1998-11-20 2008-03-15 Hoffmann La Roche Piperidin ccr-3 rezeptor-hemmer
EP1217000A1 (en) * 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
FR2861073B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
KR100976063B1 (ko) * 2007-03-16 2010-08-17 동아제약주식회사 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법
WO2008130151A1 (en) 2007-04-19 2008-10-30 Dong-A Pharm. Co., Ltd. Dpp-iv inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity
US8642772B2 (en) 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
WO2010062959A1 (en) 2008-11-26 2010-06-03 Aryx Therapeutics, Inc. 5-ht4 receptor agonists for treating irritable bowel syndrome and colonic hypersensitivity
KR20110107287A (ko) 2010-03-24 2011-09-30 동아제약주식회사 비알콜성 지방간 질환의 예방 및 치료용 약학적 조성물
US20130317052A1 (en) 2010-11-24 2013-11-28 Dong-A St Co., Ltd. Quinoline derivative compound, method for preparing same, and pharmaceutical composition containing same
SG190914A1 (en) 2010-11-24 2013-07-31 Dong A St Co Ltd Quinoline derivative compound, method for preparing same, and pharmaceutical composition containing same
KR101341692B1 (ko) 2011-03-16 2013-12-20 동아에스티 주식회사 복합생약추출물을 함유하는 당뇨병성 말초 신경병증의 치료 및 예방을 위한 조성물
KR101341693B1 (ko) 2011-03-16 2013-12-16 동아에스티 주식회사 생약추출물을 함유하는 퇴행성 신경질환의 치료 및 예방을 위한 조성물

Also Published As

Publication number Publication date
ES2594708T3 (es) 2016-12-22
EP2560955B1 (en) 2016-06-29
US20130085160A1 (en) 2013-04-04
WO2011132901A2 (en) 2011-10-27
CN102844301B (zh) 2015-04-22
AU2011243393A1 (en) 2012-10-18
BR112012026509A2 (pt) 2017-10-31
EP2560955A4 (en) 2013-09-11
CA2794176A1 (en) 2011-10-27
NZ602612A (en) 2014-11-28
KR20110118446A (ko) 2011-10-31
UA107702C2 (xx) 2015-02-10
SG184350A1 (en) 2012-11-29
CN102844301A (zh) 2012-12-26
WO2011132901A3 (en) 2012-01-26
AU2011243393B2 (en) 2014-07-17
RU2536688C2 (ru) 2014-12-27
JP2013525344A (ja) 2013-06-20
IL222491A0 (en) 2012-12-31
JP5564147B2 (ja) 2014-07-30
HK1176061A1 (en) 2013-07-19
EP2560955A2 (en) 2013-02-27
MY162554A (en) 2017-06-15
MX2012011721A (es) 2012-12-17
CA2794176C (en) 2015-12-15
RU2012150037A (ru) 2014-05-27
KR101180174B1 (ko) 2012-09-05
ZA201207903B (en) 2013-06-26
IL222491A (en) 2016-07-31
PH12012501843A1 (en) 2013-01-07
US9221790B2 (en) 2015-12-29

Similar Documents

Publication Publication Date Title
BR112014010169B1 (pt) Compostos de derivado n-tienilbenzamida substituída com aminoalquil, composição contendo os ditos compostos e uso dos mesmos para prevenir ou tratar hiperfosfatemia
CN102803235A (zh) 选择性调节cb2受体的化合物
JPH09507484A (ja) 置換モルホリン誘導体およびその治療剤としての使用
BRPI0414105B1 (pt) Compostos de benzimidazolona com atividade agonista do receptor 5-HT4
BRPI0620081B1 (pt) Composto e composição farmacêutica
BRPI0915876B1 (pt) Composto azol, composição farmacêutica e uso do dito composto para tratamento da dor neuropática
BRPI0808758A2 (pt) Derivados de benzamida e processo para o preparo dos mesmos
WO2021233427A1 (zh) 并环化合物及其制备方法、药物组合物和应用
RU2536688C2 (ru) Новые бензамидные производные
BR112020005174A2 (pt) composto que possui estrutura cíclica
TWI299992B (en) Naphthaline derivatives
KR101523776B1 (ko) 베타-락타민 페닐알라닌, 시스테인 그리고 세린 바소프레신길항물질
ES2379734T3 (es) Derivado de pirrol o sal del mismo
BR112019011758A2 (pt) derivado de azaciclobutil triazol de grupo de anel condensado, método de preparação do mesmo e uso do mesmo em medicina
JP2007217282A (ja) 置換ピリミジン誘導体
TW200922585A (en) Amino 1,2,4-triazole derivatives as modulators of mGluR5
JPH07505868A (ja) 置換フェニルカルバメート類および尿素類
TW200924774A (en) Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mGluR5
CN107074816B (zh) 一种杂环衍生物及其制备方法和在医药上的用途
TW200922586A (en) Thiophene 1,2,4-triazole derivatives as modulators of mGluR5
WO2002006272A1 (fr) Derives de polyfluoroalkyltriazole, leur preparation et leur utilisation en therapeutique
HK1176061B (zh) 新苯甲酰胺衍生物
CN117105872A (zh) 苯并二氮杂䓬类化合物及其制备方法与用途
JPH04210970A (ja) ベンズアミド誘導体及びその中間体
HK1174335A (en) Compounds which selectively modulate the cb2 receptor

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/04/2011, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2823 DE 11-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.